Posaconazole NDC 60687-523

NDC codes

FDA NDC Directory

Product NDC (as listed)60687-523Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60687-0523Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60687-523-21	60687052321	30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-523-21) / 1 TABLET, DELAYED RELEASE in 1 BLISTER PACK (60687-523-11)Marketed from Jun 11, 2020
60687-523-94	60687052394	20 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-523-94) / 1 TABLET, DELAYED RELEASE in 1 BLISTER PACK (60687-523-11)Marketed from Mar 3, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Posaconazole
Generic name (nonproprietary): posaconazole
Active ingredients: Posaconazole — 100 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: American Health Packaging
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212411
Marketing start: Jun 11, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Azoles (Chemical structure)
Identifiers: Product ID 60687-523_43cf3b42-f8bc-4881-e063-6294a90a3bdcSPL ID 43cf3b42-f8bc-4881-e063-6294a90a3bdcSPL set ID e809a31a-09da-46bf-bcaa-f34b7f3b54a3RxCUI 1482908UNII 6TK1G07BHZ
Pharmacologic class: Azole Antifungal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460687052321 followed by a unit qualifier and the quantity

Package 60687-0523-21. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 17, 2025.

Indications (excerpt from the label)

Posaconazole delayed-release tablets is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft‑versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: (1.2) Posaconazole delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kg (1) 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posac…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212411

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212411
Product	Strength	Form · route	Labeler	Product NDC
Posaconazoleposaconazole delayed-release	Posaconazole 100 mg/1	TabletOral	Chartwell RX, LLC	62135-429
Posaconazole	Posaconazole 100 mg/1	Tablet, Delayed releaseOral	Lannett Company Inc.	0527-2133
Posaconazole	Posaconazole 100 mg/1	Tablet, Delayed releaseOral	ATLANTIC BIOLOGICALS CORP.	17856-2133